Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo de revisión (ReviewArticle)

Subclinical atherosclerosis and brain health in midlife: Rationale and design of the PESA-Brain study.

  • Tristão-Pereira, Catarina
  • Fuster, Valentin
  • Lopez-Jimenez, Alejandro
  • Fernández-Pena, Alberto
  • Semerano, Aurora
  • Fernandez-Nueda, Irene
  • Garcia-Lunar, Ines
  • Ayuso, Carmen
  • Sanchez-Gonzalez, Javier
  • Ibanez, Borja
  • Gispert, Juan Domingo
  • Cortes-Canteli, Marta
  • Tristão-Pereira, Catarina
  • Fuster, Valentin
  • Lopez-Jimenez, Alejandro
  • Fernández-Pena, Alberto
  • Semerano, Aurora
  • Fernandez-Nueda, Irene
  • Garcia-Lunar, Ines
  • Ayuso, Carmen
  • Sanchez-Gonzalez, Javier
  • Ibanez, Borja
  • Gispert, Juan Domingo
  • Cortes-Canteli, Marta
Cognitive decline and dementia have been reportedly linked to atherosclerosis, the main cause of cardiovascular disease. Cohort studies identifying early brain alterations associated with subclinical atherosclerosis are warranted to understand the potential of prevention strategies before cerebral damage becomes symptomatic and irreversible. The Progression of Early Subclinical Atherosclerosis (PESA) study is a longitudinal observational cohort study that recruited 4,184 asymptomatic middle-aged individuals (40-54 years) in 2010 in Madrid (Spain) to thoroughly characterize subclinical atherosclerosis development over time. In this framework, the PESA-Brain study has been designed to identify early structural, functional and vascular brain changes associated with midlife atherosclerosis and cardiovascular risk factors. The PESA-Brain study targets 1,000 participants at the 10-year follow-up PESA visit and consists of thorough neuropsychological testing, advanced multimodal neuroimaging, and quantification of blood-based neuropathological biomarkers. We hypothesize that, in middle-age, the presence of cardiovascular risk factors and a high burden of subclinical atherosclerosis will be associated with structural, functional and vascular brain alterations, greater amyloid burden and subtle cognitive impairment. We further hypothesize that the link between subclinical atherosclerosis and poor brain health in midlife will be mediated by cerebrovascular pathology and intracranial atherosclerosis. Enrollment dates: The PESA-Brain study started in October 2020 and is estimated to be completed by December 2024. Conclusion: This study is in a unique position to unveil novel relationships between cardiovascular and brain alterations in the health-to-disease transition, which may have important implications for interventional and therapeutic approaches.
Repisalud
Publicación Artículo de revisión (ReviewArticle)

Brain JNK and metabolic disease.

  • Nogueiras, Rubén
  • Sabio, Guadalupe
Obesity, which has long since reached epidemic proportions worldwide, is associated with long-term stress to a variety of organs and results in diseases including type 2 diabetes. In the brain, overnutrition induces hypothalamic stress associated with the activation of several signalling pathways, together with central insulin and leptin resistance. This central action of nutrient overload appears very rapidly, suggesting that nutrition-induced hypothalamic stress is a major upstream initiator of obesity and associated diseases. The cellular response to nutrient overload includes the activation of the stress-activated c-Jun N-terminal kinases (JNKs) JNK1, JNK2 and JNK3, which are widely expressed in the brain. Here, we review recent findings on the regulation and effects of these kinases, with particular focus on the hypothalamus, a key brain region in the control of energy and glucose homeostasis. JNK1 blocks the hypothalamic-pituitary-thyroid axis, reducing energy expenditure and promoting obesity. Recently, opposing roles have been identified for JNK1 and JNK3 in hypothalamic agouti gene-related protein (AgRP) neurons: while JNK1 activation in AgRP neurons induces feeding and weight gain and impairs insulin and leptin signalling, JNK3 (also known as MAPK10) deletion in the same neuronal population produces very similar effects. The opposing roles of these kinases, and the unknown role of hypothalamic JNK2, reflect the complexity of JNK biology. Future studies should address the specific function of each kinase, not only in different neuronal subsets, but also in non-neuronal cells in the central nervous system. Decoding the puzzle of brain stress kinases will help to define the central stimuli and mechanisms implicated in the control of energy balance. Graphical abstract.
Repisalud
Publicación Artículo de revisión (ReviewArticle)

Stress kinases in the development of liver steatosis and hepatocellular carcinoma.

  • Cicuéndez, Beatriz
  • Ruiz-Garrido, Irene
  • Mora, Alfonso
  • Sabio, Guadalupe
Non-alcoholic fatty liver disease (NAFLD) is an important component of metabolic syndrome and one of the most prevalent liver diseases worldwide. This disorder is closely linked to hepatic insulin resistance, lipotoxicity, and inflammation. Although the mechanisms that cause steatosis and chronic liver injury in NAFLD remain unclear, a key component of this process is the activation of stress-activated kinases (SAPKs), including p38 and JNK in the liver and immune system. This review summarizes findings which indicate that the dysregulation of stress kinases plays a fundamental role in the development of steatosis and are important players in inducing liver fibrosis. To avoid the development of steatohepatitis and liver cancer, SAPK activity must be tightly regulated not only in the hepatocytes but also in other tissues, including cells of the immune system. Possible cellular mechanisms of SAPK actions are discussed.
Repisalud
Publicación Artículo de revisión (ReviewArticle)

Unidirectional association of clonal hematopoiesis with atherosclerosis development.

  • Díez-Díez, Miriam
  • Ramos-Neble, Beatriz L
  • de la Barrera, Jorge
  • Silla-Castro, J C
  • Quintas, Ana
  • Vázquez, Enrique
  • Rey-Martín, M Ascensión
  • Izzi, Benedetta
  • Sánchez-García, Lucía
  • García-Lunar, Inés
  • Mendieta, Guiomar
  • Mass, Virginia
  • Gómez-López, Nuria
  • Espadas, Cristina
  • González, Gema
  • Quesada, Antonio J
  • García-Álvarez, Ana
  • Fernández-Ortiz, Antonio
  • Lara-Pezzi, Enrique
  • Dopazo, Ana
  • Sánchez-Cabo, Fátima
  • Ibáñez, Borja
  • Andrés, Vicente
  • Fuster, Valentín
  • Fuster, José J
Clonal hematopoiesis, a condition in which acquired somatic mutations in hematopoietic stem cells lead to the outgrowth of a mutant hematopoietic clone, is associated with a higher risk of hematological cancer and a growing list of nonhematological disorders, most notably atherosclerosis and associated cardiovascular disease. However, whether accelerated atherosclerosis is a cause or a consequence of clonal hematopoiesis remains a matter of debate. Some studies support a direct contribution of certain clonal hematopoiesis-related mutations to atherosclerosis via exacerbation of inflammatory responses, whereas others suggest that clonal hematopoiesis is a symptom rather than a cause of atherosclerosis, as atherosclerosis or related traits may accelerate the expansion of mutant hematopoietic clones. Here we combine high-sensitivity DNA sequencing in blood and noninvasive vascular imaging to investigate the interplay between clonal hematopoiesis and atherosclerosis in a longitudinal cohort of healthy middle-aged individuals. We found that the presence of a clonal hematopoiesis-related mutation confers an increased risk of developing de novo femoral atherosclerosis over a 6-year period, whereas neither the presence nor the extent of atherosclerosis affects mutant cell expansion during this timeframe. These findings indicate that clonal hematopoiesis unidirectionally promotes atherosclerosis, which should help translate the growing understanding of this condition into strategies for the prevention of atherosclerotic cardiovascular disease in individuals exhibiting clonal hematopoiesis.
Repisalud
Publicación Artículo de revisión (ReviewArticle)

Cardioprotection strategies for anthracycline cardiotoxicity.

  • Moreno-Arciniegas, Andrea
  • Cádiz, Laura
  • Galán-Arriola, Carlos
  • Clemente-Moragón, Agustín
  • Ibáñez, Borja
Thanks to the fantastic progress in cancer therapy options, there is a growing population of cancer survivors. This success has resulted in a need to focus much effort into improving the quality of life of this population. Cancer and cardiovascular disease share many common risk factors and have an interplay between them, with one condition mechanistically affecting the other and vice versa. Furthermore, widely prescribed cancer therapies have known toxic effects in the cardiovascular system. Anthracyclines are the paradigm of efficacious cancer therapy widely prescribed with a strong cardiotoxic potential. While some cancer therapies cardiovascular toxicities are transient, others are irreversible. There is a growing need to develop cardioprotective therapies that, when used in conjunction with cancer therapies, can prevent cardiovascular toxicity and thus improve long-term quality of life in survivors. The field has three main challenges: (i) identification of the ultimate mechanisms leading to cardiotoxicity to (ii) identify specific therapeutic targets, and (iii) more sensible diagnostic tools to early identify these conditions. In this review we will focus on the cardioprotective strategies tested and under investigation. We will focus this article into anthracycline cardiotoxicity since it is still the agent most widely prescribed, the one with higher toxic effects on the heart, and the most widely studied.
Repisalud
Publicación Artículo de revisión (ReviewArticle)

Circadian Effects on Vascular Immunopathologies.

  • Zeng, Qun
  • Oliva, Valeria Maria
  • Moro, María Ángeles
  • Scheiermann, Christoph
Circadian rhythms exert a profound impact on most aspects of mammalian physiology, including the immune and cardiovascular systems. Leukocytes engage in time-of-day-dependent interactions with the vasculature, facilitating the emigration to and the immune surveillance of tissues. This review provides an overview of circadian control of immune-vascular interactions in both the steady state and cardiovascular diseases such as atherosclerosis and infarction. Circadian rhythms impact both the immune and vascular facets of these interactions, primarily through the regulation of chemoattractant and adhesion molecules on immune and endothelial cells. Misaligned light conditions disrupt this rhythm, generally exacerbating atherosclerosis and infarction. In cardiovascular diseases, distinct circadian clock genes, while functioning as part of an integrated circadian system, can have proinflammatory or anti-inflammatory effects on these immune-vascular interactions. Here, we discuss the mechanisms and relevance of circadian rhythms in vascular immunopathologies.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Journey to the Core of the Plant Cell Cycle

  • Gutiérrez Armenta, Crisanto
Production of new cells as a result of progression through the cell division cycle is a fundamental biological process for the perpetuation of both unicellular and multicellular organisms. In the case of plants, their developmental strategies and their largely sessile nature has imposed a series of evolutionary trends. Studies of the plant cell division cycle began with cytological and physiological approaches in the 1950s and 1960s. The decade of 1990 marked a turn point with the increasing development of novel cellular and molecular protocols combined with advances in genetics and, later, genomics, leading to an exponential growth of the field. In this article, I review the current status of plant cell cycle studies but also discuss early studies and the relevance of a multidisciplinary background as a source of innovative questions and answers. In addition to advances in a deeper understanding of the plant cell cycle machinery, current studies focus on the intimate interaction of cell cycle components with almost every aspect of plant biology., Research in the author’s laboratory is currently funded by Ministerio de Ciencia e Innovación and Fondo Europeo de Desarrollo Regional FEDER grant RTI2018-094793-B-I00, by H2020 European Research Council grant ERC-2018-AdG_833617, and by institutional grants from Banco de Santander and Fundación Ramon Areces to the Centro de Biología Molecular Severo Ochoa.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Peptides Acting as Cognitive Enhancers

  • Asua, Diego
  • Bougamra, Ghassen
  • Calleja-Felipe, María
  • Morales, Miguel
  • Knafo, Shira
The aim of this paper is to present an overview of three peptides that, by improving synaptic function, enhance learning and memory in laboratory rodents. We summarize their structure, their mechanisms of action, and their effects on synaptic and cognitive function. First we describe FGL, a peptide derived from the neural cell adhesion molecule which improves cognition by the activation of the PKC pathway that triggers an activity-dependent delivery of AMPA receptors to the synapses. Then we describe PTD4-PI3KAc peptide that by activating PI3K signaling pathway it promotes synapse and spine formation and enhances hippocampal dependent memory. Lastly, we describe a new peptide derived from the well-known tumor suppressor PTEN that prevents pathological interactions between PTEN and PDZ proteins at synapses during exposure to Amyloid beta. This action prevents memory deterioration in mouse model of Alzheimer's disease. Together, this review indicates how learning and memory can be improved by manipulating synaptic function and number through pharmacological treatment with peptides, and it establishes synaptic function as a valid target for cognitive enhancement., The original work from the authors contributing to this review has been supported by grants from the Ministerio de Economía y Competitividad (SAF2016-78071-R and SAF2015-62540-ERC, Spain) from the Alzheimer’s Association (NIRG-13-279533), the Basque Ministry of Health (2013111138), Basque Business Development Agency (SPRI-Elkartek), the University of the Basque Country (EHUrOPE14/03), and the Ikerbasque Foundation., Peer reviewed